.png?sfvrsn=6d0e27cd_1 "Partnership for Change - v7 (1)")
By Murdoch Children’s Research Institute
Tuberculosis (TB) is one of the world's leading infectious killers. Although it is curable, drug-resistant TB is a growing problem. However, millions of infected people are either not diagnosed or not treated, putting them at risk of dying and/or infecting others. While the BCG vaccine is effective in preventing severe forms of TB in young children, it does not adequately protect adults and adolescents, who account for most transmission. In this webinar we will hear more about why we need to develop a new vaccine, the limitations of the current vaccine and what new vaccines are on the horizon and the challenges associated with their development.
Join us online for this free event, everyone is welcome! Contact asiapacific.health@mcri.edu.au with any questions.
Co-Chairs:
Professor Steve Graham
Group Leader, International Child Health, Murdoch Children’s Research Institute Professor of International Child Health, Department of Paediatrics, The University of Melbourne
Professor Fiona Russell
Group Leader, Asia-Pacific Health, Murdoch Children’s Research Institute Director, Child and Adolescent Health PhD Program, Department of Paediatrics, The University of Melbourne
Burden of tuberculosis and multidrug resistant tuberculosis
Dr Trisasi Lestari
Researcher and Lecturer, Center for Tropical Medicine, Universitas Gadjah Mada
Research Consultant, Menzies School of Health Research
Limitations of BCG vaccine and challenges of developing a new vaccine
Professor Nigel Curtis
Group Leader, Infectious Diseases, Murdoch Children’s Research Institute
Head, Infectious Diseases, The Royal Children’s Hospital Melbourne
What new vaccines are on the horizon?
Professor Jamie Triccas
Professor of Medical Microbiology and Theme Leader, Immunity and Inflammation, School of Medical Sciences, The University of Sydney
About the Asia-Pacific Vaccine Research Network